| Number: GOG 0076HH |
Principal Investigator: Mutch, David |
| Title: A Limited Access Phase I/II Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Velaparib) (IND #77840) in the Treatment of Advanced, Persistent, or Recurrent Carcinomas of Cervix |
| Description: The purpose of the first part of this study (called Phase I) is to test how safe ABT-888 is and to determine the appropriate dose of ABT-888 to be used in the Phase II part of the study. If you enter the study on the Phase I portion, the dose of ABT-888 you will receive will depend on when you enter...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201109278 |
Principal Investigator: Esthappan, Jacqueline |
| Title: Phase I/II Novel Magnetic Resonance Imaging Sequences for Target Delineation and Prognostication in Cervical Cancer |
| Description: Cervical cancer is typically treated with a combination of radiation therapy and chemotherapy called cisplatin. Magnetic
Resonance Imaging (or MR Imaging) and Computerized Tomography (CT) scans are typically used for planning radiation treatments. This study will evaluate if new kinds of MR images ...MORE |
| ___________________________________________________________________________________________________ |
| Number: ACRIN 6682 |
Principal Investigator: Dehdashti, Farrokh |
| Title: Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer |
| ___________________________________________________________________________________________________ |
| Number: 201104322 |
Principal Investigator: Grigsby, Perry |
| Title: FDG Tumor Heterogeneity during Chemoradiation as a Predictor of Response to Concurrent Radiation Therapy and Chemotherapy in Patients with Cervical Cancer |
| Description: The purpose of this research study is to see if positron emission tomography (PET imaging) with 18Ffluorodeoxyglucose (FDG – a radioactive form of sugar) can help doctors determine which patients will respond best to traditional treatment versus those that need more aggressive therapy to prevent the...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201210087 |
Principal Investigator: Novetsky, Akiva |
| Title: Etiology of fever in non-operative gynecologic oncology patients |
| ___________________________________________________________________________________________________ |
| Number: 201105400 |
Principal Investigator: Mutch, David |
| Title: Formation of a Tissue Bank for Gynecologic Malignancies |
| Description: The purpose of this study is to collect specimens (i.e., tissue obtained during surgery and/or blood) and related information from women who are undergoing surgery for a gynecologic condition. Specimens and related information that are collected for this research study will be used for future cance...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201301140 |
Principal Investigator: Ioffe, Yevgenita |
| Title: Overall and progression free survival in patients with cervical cancer and supraclavicular metastases at the time of initial presentation |
| ___________________________________________________________________________________________________ |
| Number: 201110166 |
Principal Investigator: Lane, Michael |
| Title: Clinical Impact of a Quality Improvement Intervention to Improve Cervical Cancer Screening in Women with HIV |
| ___________________________________________________________________________________________________ |
| Number: 201108327 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107068 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment |
| Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102462 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies |
| Description: The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This stu...MORE |
| ___________________________________________________________________________________________________ |